36results about How to "Increase drug sensitivity" patented technology

The present invention relates to a peptide having eight amino acid sequences derived from CAGE and retaining anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug resistant cancer cells and, specifically, to a peptide, which has an amino acid sequence of SEQ ID NO: 1 (AQTGTGKT) and thus binds to the CAGE protein, thereby inhibiting an inter-linkage between CAGE and GSK3β, thus exhibiting anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug resistant cancer cells, and to a pharmaceutical composition, containing the peptide, for anticancer use or anticancer drug aiding.

The invention relates to a construction method for an acute hyperuricemia tree shrew model. The method comprises the following steps: (1) selecting adult healthy tree shrew with body weight of 110 to 150 g and an age of 1 to 3 years; (2) respectively measuring fasting serum uric acid values of males and females of tree shrew selected in the step (1); (3) carrying out conventional breeding on the tree shrew selected in the step (1) and pretreating the tree shrew by grasping and releasing the tree shrew with hand; and (4) injecting the tree shrew treated in the step (3) with an oteracil potassium suspension so as to obtain the acute hyperuricemia tree shrew model, wherein the amount of the used oteracil potassium suspension is 40 mg / kg to 100 mg / kg on the basis of the body weight of the tree shrew. The model has typical disease symptoms, a quantity index has statistical significance, and serum urea nitrogen and serum creatinine values and histopathological results prove that such a model making dosage range is safe and does not result in influence on the liver and the kidney.

The present application provides an extracellular regulatory protein kinase probe as shown in formula I, the A loop on the structure can specifically target the cysteine ​​at position 178 of the inactive site on the outside of the ERK1 / 2 kinase structure Amino acid covalently combined, can effectively target ERK1 / 2; and the extracellular regulatory protein kinase probe will not inhibit the ability of ERK1 / 2 to bind to ATP and the kinase activity, but through its targeting of ERK1 / 2, Provide small molecule guiding groups for protein modification and labeling research targeting ERK kinases, improve the drug sensitivity of inhibitors to extracellular regulated protein kinases, provide probes for extracellular regulated protein kinase inhibitors, and guide extracellular regulated protein kinases The inhibitor can target the extracellular regulatory protein kinase site, so that the inhibitor can work and improve the effect.

The invention relates to a PI3K and MTH1 targeting drug composition and applications thereof. The small-molecule targeting drug composition and a drug preparation provided by the invention comprise afirst preparation formed by a PI3K inhibitor or a pharmaceutically-acceptable carrier thereof, and a second preparation formed by a MTH1 inhibitor or a pharmaceutically-acceptable carrier thereof. Thecompatibility is reasonable. The combination of the two preparations can improve the drug sensitivity of the PI3K inhibitor, play the role of the MTH1 small-molecule inhibitor in the anti-tumor aspect and increase the treatment effect of the PI3K inhibitor. Experiments prove that: the combined administration of the PI3K inhibitor and the MTH1 inhibitor obviously enhances the tumor cell activity inhibition compared with the single administration, reduces the single administration dosage, can reduce the drug toxicity, is expected to become a new tumor treatment scheme aiming at the non-ideal treatment effect of the PI3K inhibitor, and has wide application prospect.

The present invention provides a tumor-targeting polypeptide, including: (a) a novel tumor-targeting therapeutic polypeptide; (b) a fusion protein formed by the polypeptide (a) and a penetrating peptide element; (c) a fusion protein formed by the polypeptide (a) or ( b) A derivative polypeptide derived by adding, deleting, or changing one or more amino acids and having effects on RAD51 ubiquitination modification, foci formation in the nucleus, and reduced DNA repair function; (d) the amino acid sequence corresponds to C of the RAD51 protein end (331-339aa), or a fusion protein formed by the C-terminus and the penetrating peptide element, and the polypeptide or fusion protein (d) can affect the ubiquitination modification of RAD51, the formation of foci in the nucleus, and reduce the DNA repair function. By administering the polypeptide of the present invention, only the ubiquitination modification of RAD51 is affected, thereby affecting the formation of foci in the nucleus, and the side effects are small; the concentration of chemotherapy drugs can be effectively reduced, and the drug sensitivity of tumor cells can be improved.

The invention relates to a pharmaceutical composition for preventing and treating poultry salmonellosis and a preparation method thereof. The pharmaceutical composition comprises the following components: artemisinic acid, ampicillin sodium, ciprofloxacin, polysaccharide + probiotic microcapsules. The pharmaceutical composition of the present invention selects active components of monomeric traditional Chinese medicines and uses them in combination with antibiotics, which can reduce the amount of conventional traditional Chinese medicines and antibiotics and improve the bioavailability and efficacy of the medicines on the premise of improving the antibacterial and killing effects. At the same time, using immune enhancement and regulation as an auxiliary treatment method, polysaccharides and probiotics are selected to regulate the intestinal flora of sick chicks and rebuild a good microbial flora, so as to strengthen the immune function of chicks and improve production performance. The pharmaceutical composition of the invention can be administered through mixed feeding, is suitable for clinical application and has definite curative effect, and is suitable for application in intensive scale farms.

The invention provides an attachment protein derived from bifidobacterium longum, and discloses the amino acid sequence thereof; on the basis, experiments discover that the attachment protein not only can attach to enterocyte, but also has the function of improving microorganism antibiotic sensitivity, and especially for escherichia coli O157:H7, the antibiotic synergy is particularly prominent. Based on the beneficial discovery, the application of the protein as an anti-bacteria synergist, escherichia coli O157:H7, is determined, so that the application range of the protein is expanded, and at the same time, a new approach is provided for improving microorganism drug sensitivity. The prominent technological effect is achieved on the basis of strict experimental measures, and a broad application prospect is obtained.